Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort.

Date publication

août 2025

Journal

Clinical lymphoma, myeloma & leukemia

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis

Tous les auteurs :
Hulin C, Belhadj Merzoug K, Royer B, Caillot D, Bobin A, Macro M, Karlin L, Mohty M, Frenzel L, Perrot A, Vincent L, Dib M, Piocell FO, Benramdane R, Calmettes C, Chalopin T, Garlantézec R, Désaméricq G, Mechiche H, Decaux O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40967989

Résumé

Carfilzomib (K) is approved in France to treat multiple myeloma in second line or later (2L+) with dexamethasone (Kd), lenalidomide and dexamethasone (KRd), daratumumab and dexamethasone (D-Kd). We assessed K utilization and outcomes in a French real-world cohort (2017-2022).

Mots clés

Dosing, Frequency of administration, Overall response rate, Proteasome inhibitor, Survival outcome

Référence

Clin Lymphoma Myeloma Leuk. 2025 08 7;: